

Secrétariat scientifique

Ces publications 2025 témoignent bien du dynamisme et de la grande diversité de la recherche au Centre Oscar Lambret, avec la valorisation de travaux en oncologie médicale, radiothérapie et radiophysique, chirurgie carcinologique, et pédiatrie.

Les publications sont réparties par Domaines. Les publications à l'initiative du COL sont précédées par ***.

Publications COL 2025

Algologie, Médecine Palliative & Soins de Support

Baudry AS, Delpuech M, Charton E, Peugniez C, Hivert B, **Carnot A**, Ceban T, Dominguez S, Lemaire A, **Aelbrecht-Meurisse C**, Anota A, Christophe V. Is intrapersonal emotional competence a personal resource for the quality of life of informal caregivers of cancer patients unlike interpersonal emotional competence? Qual Life Res 2025; 34: 377-383.

IF : 2.7. Catégorie C

Anesthésie

Dupoiron D, Bienfait F, Seegers V, Piloquet FX, Pluchon YM, Pechard M, Mezaib K, Chvetzoff G, Diaz J, **Ahmeidi A**, Mauriès-Saffon V, Lebrech N, Jubier-Hamon S. Evaluating Treatment Preferences and the Efficacy of Capsaicin 179 mg Patch vs. Pregabalin in a Randomized Trial for Postsurgical Neuropathic Pain in Breast Cancer: CAPTRANE. Cancers (Basel) 2025;17:313.

IF : 4.4. Catégorie C

Digestif

Lepage C, Phelip JM, Cany L, Barbier E, Manfredi S, Deguiral P, Laly M, Baconnier M, Jary M, Latrive JP, Terrebonne E, Lièvre A, **Jafari M**, Ben Abdelghani M, Ain JF, Breysacher G, Boillot-Benedetto I, Pelaquier A, Prost P, Ezenfis J, Rinaldi Y, Le Foll C, Berthelet O, Darut-Jouve A, Dahan L, Piche T, Lagasse JP, Bibeau F, Laurent-Puig P, Bouché O; PRODIGE 13 investigators/collaborators. Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial. Ann Oncol 2025;36:1468-1479.

IF : 65.4. Catégorie A

Blay JY, Devin Q, Toulmonde M, Dufresne A, **Penel N**, Adenis A, Rios M, Bertucci F, Duffaud F, Firmin N, Valentin T, Bompas E, Collard O, Pracht M, Hervieu A, Verret B, Ray-Coquard I, Cassier P, Henon C, Perol D, Italiano A, Chabaud S, Le Cesne A. Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial. Ann Oncol 2025; 36: 1035-1046.

IF : 65.4. Catégorie A

Ducreux M, Desgrappes R, Rinaldi Y, Di Fiore F, Guimbaud R, Evesque L, Bachet JB, Vanelslender P, Lecomte T, Capitain O, Parzy A, Bolliet M, Etienne PL, Forestier J, **El Hajbi F**, Bignon AL, Lebrun-Ly V, De Sousa Carvalho N, Texier M, Bouche O. PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. J Clin Oncol 2025; 43: 2255-2264.

IF : 43.4. Catégorie A

Walter T, Lecomte T, Hadoux J, Niccoli P, Saban-Roche L, **Gaye E**, Guimbaud R, Baconnier M, Hautefeuille V, Do Cao C, Petorin C, Hentic O, Perrier M, Aparicio T, Scoazec JY, Bonjour M, Gibert B, Hervieu V, Poncet D, Barritault M, Gerard L, Durand A; "Groupe d'étude des tumeurs endocrines (GTE)" and the French ENDOCAN-RENATEN network. Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O 6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET). J Clin Oncol 2025; 43: 960-971.

IF : 43.4. Catégorie A

Parent P, Pigneur F, Hilmi M, **Carnot A**, Garcia Larnicol ML, Vernerey D, Luciani A, Hammel P, Henriques J, Neuzillet C, Turpin A. Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity. *J Cachexia Sarcopenia Muscle* 2025; 16: e13595.

IF : 9.1. Catégorie A

Penel N, Le Cesne A, Blay JY. Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025;. *Eur J Cancer* 2025; 222: 115473.

IF : 7.1. Catégorie B

Tougeron D, Louvet C, Desramé J, Evesque L, Angelergues A, **Carnot A**, Breysacher G, Zaanani A, Etchepare N, Mabro M, Kaluzinski L, Petorin C, Chibaudel B, Aparicio T, Bodere A, Rinaldi Y, Le Malicot K, Emile JF, Lepage C, Baures A, Djamaï H, Taly V, Laurent-Puig P. Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma. *Commun Med (Lond)* 2025; 5: 136.

IF : 6.3. Catégorie B

Modesto A, Gibert S, Delmas C, Tougeron D, Paumier A, **Taillez A**, Le Sourd S, Leignel DA, Ronchin P, Jouve AD, Vendrely V, Riou O, Martin-Babau J, Leroy T, Quéro L, Hanoun N, Cordelier P, Pezzella V, Delord JP, Guimbaud R, Moyal E, Seva C. Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma-based collection of 77 patients with locally advanced unresectable esophageal cancer. *Int J Cancer* 2025. doi: 10.1002/ijc.70011.

IF : 4.7. Catégorie B

Collard MK, Mineur L, Nekrouf C, Denost Q, Rouanet P, de Chaisemartin C, Merdrignac A, **Jafari M**, Cotte E, Desrame J, Manceau G, Benoist S, Buscail E, Karoui M, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Duchalais E, Lupinacci RM, Goasguen N, Simon T, Parc Y, Lefevre JH; French Research Group of Rectal Cancer Surgery (GRECCAR). Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up. *Dis Colon Rectum* 2025; 68: 199-208.

IF : 3.7. Catégorie B

Marin H, Nuytens F, Behal H, Messier M, Degisors S, Renaud F, Eveno C, Veziant J, Piessen G. Impact of systematic enteral nutrition on postoperative complications and oncological outcome in a curative multimodal strategy for esophageal cancer. *J Gastrointest Surg*. 2025 Aug;29(8):102113. doi: 10.1016/j.gassur.2025.102113. Epub 2025 Jun 4. PMID: 40480421.

IF : 2.4. Catégorie B

Penel N, Cayeux A, Decanter G, Lebellec L. [Neoadjuvant imatinib treatment of locally advanced gastrointestinal stromal tumours: Theory and practice]. *Bull Cancer* 2025; 112: 1051-1055.

IF : 0.8. Catégorie E

Bridoux M, Aymes E, Conroy T, Gourgou S, **Carnot A**, Borg C, **Le Deley MC**, Turpin A. Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial. *ESMO Gastrointest Oncol* 2025; 7: 100119.

Catégorie NC

Gynécologie

Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileskin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, **Kaczmarek E**, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churrua C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label randomised controlled phase 3 trial. *Lancet* 2025; 405: 2205-2216.

IF : 88.5. Catégorie A+

Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Satersdal AB, Kroep JR, Gelmon K, Amant F, **Maillez A**, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjari S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial. *J Clin Oncol* 2025; 43: 2712-2719.

IF : 43.4. Catégorie A

Joly F, Leary A, Ray-Coquard I, Asselain B, Rodrigues M, Gladieff L, Meynard G, Abadie-Lacourtoisie S, Lebreton C, Bengrine Lefevre L, Fournel P, Largillier R, Selle F, Frenel JS, Fernandez Diez Y, Foa C, Follana P, Meunier J, Fabbro M, Hardy Bessard AC, Cojean-Zelek I, **Kaczmarek E**, Bonnet E, Arnaud A, Roche S, Leroy K, Just PA, Leman R, Jeanne C, Callens C, You B, Alexandre J. Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial. *Nat*

Commun 2025; 16: 7950.

IF : 15.7. Catégorie A

Piffoux M, Leary A, Follana P, **Abdeddaim C**, Joly F, Bin S, Bonjour M, Boulai A, Callens C, Villeneuve L, Alexandre M, Schwiertz V, Freyer G, Rodrigues M, You B. Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial. Nat Commun 2025; 16: 1821.

IF : 15.7. Catégorie A

Demeestere I, Niman SM, Partridge AH, Diego DS, Kammler R, Ruggeri M, Colleoni M, Shimizu C, Saura C, Gelmon KA, Saetersdal AB, Kroep JR, **Mailliez A**, Amant F, Ruiz-Borrego M, Lee JE, Kataoka A, Walshe JM, Takei J, Borstnar S, Borges VF, Saunders C, Susnjar S, Bjelic-Radisic V, Cardoso F, Meisel JL, Kawwass JF, Spanic T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr, Peccatori FA; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial. Breast 2025; 83: 104547.

IF : 7.9. Catégorie A

Dujardin C, Narducci F, Hudry D, Villers A, Marcq G, **Gomez CM**. Bricker ileal conduit diversion with ICG technique in 10 steps. Gynecol Oncol Rep 2025; 59: 101753.

IF : 4.7. Catégorie A

Ovaere C, Pasquesoone C, Narducci F, El Hajj H. Isolated nodal involvement in early-stage ovarian serous borderline tumor. Int J Gynecol Cancer 2025; 35: 101892.

IF : 4.7. Catégorie A

Manzour N, Chiva L, Zanagnolo V, Căpîlna ME, Bizzarri N, Mom CH, Klasa Ł, Arencibia O, Malzoni M, **Narducci F**, Raspagliesi F, Poka R, Golub D, Tavares M, Tsolakidis D, Shamistan A, Perrone AM, Pete I, Aluloski I, Bernardino M, Vujić G, Jedryka M, Maenpaa M, Ponce J, Povolotskaya N, Roldan Rivas F, Feron JG, Van Gorp T, Alonso-Espías M, Fruscio R, Vorgias G, Díez García J, Herrero S, Kavallaris A, Luyckx M, Yezhova I, Mitrovic M, Ferrero A, Saaron R, Sukhin V; SUCCOR 10-Year Study Group. SUCCOR 10 years: a decade's perspective on radical hysterectomy outcomes in cervical cancer. Int J Gynecol Cancer 2025; 35: 101690.

IF : 4.7. Catégorie A

Navarro AS, Ricotta G, Gauroy E, Martinez A, Ferron G. Urinary reconstruction using enterocystoplasty after partial cystectomy in surgical recurrence of cervical cancer. Int J Gynecol Cancer 2025; 35: 101813.

IF : 4.7. Catégorie A

Fidlers T, Giroux PA, Hudry D, Cordoba A, Narducci F, Martinez-Gomez C. Gracilis flap for vulvar reconstruction in 10 steps. Int J Gynecol Cancer 2025; 35: 101628.

IF : 4.7. Catégorie A

Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, Rouge TM, Sabatier R, Classe JM, Petit T, **Leblanc E**, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M. Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas. Int J Gynecol Cancer 2025; 35: 101866.

IF : 4.7. Catégorie A

Le Saux O, McNeish I, D'Incalci M, **Narducci F**, Ray-Coquard I. Controversies in the management of serous tubal intra-epithelial carcinoma lesions of the fallopian tube. Int J Gynecol Cancer 2025; 35: 101667.

IF : 4.7. Catégorie A

Matulonis UA, Herrstedt J, Oza A, Mahner S, Redondo A, Berton D, Berek JS, Haslund CA, Marmé F, González-Martín A, **Bécourt S**, Tinker AV, Ledermann JA, Benigno B, Lindahl G, Colombo N, Malinowska IA, Liu W, Bains M, Monk BJ, Mirza MR. ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety. Gynecol Oncol 2025; 195: 192-199.

IF : 4.1. Catégorie A

Chator C, Chevrier M, Frenel JS, Guyon F, Sabatier R, Pomel C, Rouge TM, Pautier P, Gladieff L, Follana P, Colombo PE, Petit T, Guillemet C, Marchal F, **Narducci F**, Fumet JD, Rodrigues M, Bosquet L, Rouzier R, Ray-Coquard I. Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database. Gynecol Oncol 2025; 201: 17-25.

IF : 4.1. Catégorie A

Luxey X, **Lemoine A**, Dewinter G, Joshi GP, Le Ray C, Raeder J, Van de Velde M, Bonnet MP; PROSPECT Working Group of the European Society of Regional Anesthesia and Pain Therapy. Acute pain management after vaginal delivery with perineal tears or episiotomy. Reg Anesth Pain Med. 2025;50:503-513.

IF : 3.5. Catégorie B

Schoenen S, Martinez Gomez C, Pasquesoone C, Alline J, Duchatelet M, Risbourg S, Mailliez A, Ben Miled A, Saint-Ghislain M, Serouart B, Fidlers T, Bresson L, Navarro AS, Le Deley MC, Narducci F. Evaluation of risk-reducing radical fimbriectomy followed by delayed oophorectomy in high-risk Women: A single-center retrospective study. Eur J Surg Oncol 2025; 51: 110469.

IF : 2.9. Catégorie B

Le Saux O, Sabatier R, Treilleux I, Renaud LI, Brachet PE, Martinez A, Frenel JS, **Abdeddaim C**, Berthet J, Barrin S, Colombe-Vermorel A, Odeyer L, Lainé A, Caux C, Dubois B, Ray-Coquard I. Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy. Ther Adv Med Oncol 2025; 17: 17588359251347364.

IF : 4.2. Catégorie C

Leman R, Cherifi F, Leheurteur M, Theret P, **Pasquesoone C, Saint-Ghislain M, Bresson L**, Denoyelle C, Vigneron N, Poulain L, Delepee R, Berby B, Dremaux J, Dumont A, Blanc-Fournier C, Jeanne C, Briand M, Rousseau N, Pepin LF, Deruche E, Dumont F, Leconte A, Lequesne J, Clarisse B, Joly F, Castera L, Rouzier R. Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO). BMC Cancer 2025; 25: 1075.

IF : 3.4. Catégorie C

Carrot A, Corbaux P, Colombar O, Lebreton C, Gladieff L, Tredan O, Selle F, **Abdeddaim C**, Leary A, D'Hondt V, Dubot C, Reverdy T, You B, Freyer G. Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study. CPT Pharmacometrics Syst Pharmacol 2025; 14: 1310-1321.

IF : 3. Catégorie C

Alexandre J, Boudier P, Lavit E, Asselain B, Emambux S, Berton D, Babin G, Lescure C, Heudel PE, Salaun H, Delanoy N, Dawood H, Combe P, Duliège D, Selle F, Hakmé A, Cagnan L, Offner N, Niogret J, Pautier P, Sellam Z, Gomes David M, Monard A, Hardy-Bessard AC, **Bellier C**, Lortholary A, Chaix M, Follana P, Deiana L, Gavoille L, Manuceau G, Djennaoui S, Cancel M, Kalbacher E, De Percin S. Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study. BMJ Open 2025; 15: e096837.

IF : 2.3. Catégorie C

Schoenen S, Fidlers T, Bresson L, Narducci F, Giroux PA, Gomez CM. Full-thickness inguinal resection with abdominal flap transposition for inguinal recurrence of vulvar cancer in an irradiated field. Gynecol Oncol Rep 2025; 59: 101734.

IF : 1.3. Catégorie D

Fidlers T, Narducci F, Pasquesoone C, Hudry D, Mailliez A, Becourt S, Miled AB, Leblanc E, Gómez CM. [Is there a place for prophylactic fimbriectomy followed by delayed ovariectomy?]. Bull Cancer 2025; 112: 316-325.

IF : 0.8. Catégorie E

Ongaro S, Desreux J, Tremblay-Lemoine PL, **Schoenen S**, Kakkos A, Doyen J, Kridelka F, Goffin F. Comment j'explore ...Actualité dans le dépistage du cancer du col utérin : implémentation du test hr-HPV [Cervical cancer screening : implementation of the hr-HPV test]. Rev Med Liege 2025;80:729-734.

Immunothérapie

Cottu A, Delaval L, **Forestier A**, Tomelleri A, Campochiaro C, Bond M, Dion J, Gury A, Savary X, Dhote R, Betrains A, Bouillet L, Liozon E, Bories E, Petitdemange A, Legendre P, Crichi B, Kerschen P, Carneiro Esteves L, Armengol G, Outh R, Al Tabaa O, Wolff L, Ilzkovitz M, Cherif MY, Laparra A, Dagna L, Bruneval P, Terrier B. Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study. Rheumatology (Oxford) 2025; 64: 4546-4554.

IF : 4.4. Catégorie B

Pédiatrie/AJA

Lervat C. Sarcomes et dispositifs adolescents et jeunes adultes [Sarcomas and devices for adolescents and young adults]. Rev Prat. 2025;75:981-982.

IF : 65.4. Catégorie A

Bisogno G, Chisholm J, Hladun R, De Salvo GL, Guerin F, Casanova M, Mandeville H, Alaggio R, Coppadoro B, Orbach D, Ferrari A, van Rijn R, **Defachelles AS**, Ben-Arush M, Glosli H, Cesen M, Merks JHM, Minard-Colin V. Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial. J Clin Oncol 2025; 43: 1856-1862.

IF : 43.4. Catégorie A

Filser M, Torrejon J, Merchadou K, Dufour C, Girard E, Bourneix C, Lemaître E, Gharsalli T, Brillet R, Wong J, Gentien D, Rapinat A, Servant N, Vasiljevic A, Bertozzi AI, **Raimbault S**, Tauziède Espariat A, Lhermitte B, Faure-Conter C, Icher C, Berger C, Maurage CA, Bodet D, Meyronet D, Uro-Coste E, De Carli E, Forest F, Palenzuela G, Chotard G, Gauchotte G, **Sudour H**, Mansuy L, Deparis M, Tallegas M, Faisant M, Entz-Werle N, Varlet P, Leblond P, Michalak-Provost S, Proust Houdemont S, Rigau V, Doz F, Delattre O, Bourdeaut F, Ayrault O, Masliah-Planchon J. Nanopore sequencing as a cutting-edge technology for medulloblastoma classification. *Neuro Oncol* 2025; 27: 1313-1324.

IF : 13.4. Catégorie A

Defachelles AS, Breunis WB, Casanova M, Minard-Collin V, Hjadun R, Wasti A, Dávila Fajardo R, Terwisscha van Scheltinga S, Heenen D, Heinz AT, Sparber-Sauer M, Merks JHM, Chisholm JC, Gatz SA. Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG). *Br J Cancer* 2025; 133: 1591-1598.

IF : 6.8. Catégorie B

Rossillon L, Thomas-Teinturier C, Orbach D, Tabone MD, Bertrand A, Ansoborlo S, **Defachelles AS**, Rome A, Haouy S, Plantaz D, Bolle S, Bernier-Chastagner V, Guerin F, Sarnacki S, Philippe-Chomette P, Allodji R, Lenez L, Métayer L, Barraud-Lange V, Minard-Colin V, Fresneau B. Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in France. *Cancer* 2025; 131: e35918.

IF : 5.1. Catégorie B

Demoor-Goldschmidt C, Lamore K, Jakab Z, de Ville de Goyet M, Heinrich S, Bathilde L, Berger C, Beek L, Beauchesne M, Borszekine Cserhati E, Brichard B, Constine LS, Te Dorsthorst J, Favreau M, Grabow D, Hinckel L, Keresztes A, Ollivier L, Sauterey B, Skinner R, **Thebault E**, Thierry-Chef I, Trinh S, Zadavec Zaletel L, Roganovic J, Chades-Esnault MC, Armand A. Addressing Akasia in Childhood Adolescent and Young Adult Cancer Survivors: Implications for Long-Term Follow-Up and Preventive Health Interventions. *Cancers (Basel)* 2025; 17.

IF : 4.4. Catégorie C

Wasti AT, Bisogno G, Hladun R, **Defachelles AS**, Casanova M, Breunis WB, Gatz SA, Schoot RA, Ferrari A, Jenney M, Alaggio R, Davila Fajardo R, Terwisscha van Scheltinga S, Shipley J, Meister MT, R van Rijn R, Anderson J, Sparber-Sauer M, Chisholm JC, Merks JHM. Childhood, Adolescent and Young Adult Poor-Prognosis Rhabdomyosarcoma. *Cancers (Basel)* 2025; 17: 3100.

IF : 4.4. Catégorie C

Pacaud C, Nazon C, Pages M, Rouger J, Berthet P, Winter S, **Thebault É**, Faure-Conter C, Berger C, Paillard C. Management of Paediatric Cancers Associated With Bloom Syndrome. *Hum Mutat.* 2025 Jul 3;2025:7065233. doi: 10.1155/humu/7065233. PMID: 40641635; PMCID: PMC12245492.

IF : 3.7. Catégorie C

Savagner J, Munzer C, Schleiermacher G, Garaventa A, Haupt R, Sorrentino S, Mazzocco K, Di Cataldo A, Canete A, Segura V, Ramal D, Wheeler K, Ladenstein R, de Lacerda AF, Brichard B, Beck-Popovic M, Valteau-Couanet D, Pasqualini C, Coze C, Dumont B, **Defachelles AS**, Gambart M. Neuroblastoma in Infants: Long-Term Survival From INES Protocols A SIOPEN Study. *Pediatr Blood Cancer* 2025; 72: e31982.

IF : 2.3. Catégorie C

Moisan R, Wallet J, Aubert S, Boudou-Rouquette P, Gaspar N, Marec-Bérard P, **Thebaud E**, Bompas E, Pinieux G, Jouve JL, Italiano A, Chevreau C, Blay JY, **Lervat C**; GSF-GETO, ResOs, and NETSARC+ networks. Insights Into Non-Classic Primary Bone Sarcomas in Children Adolescents and Young Adults: A French Descriptive Study. *Pediatr Blood Cancer* 2025; 72: e31931.

IF : 2.3. Catégorie C

Berlanga P, Aerts I, Corradini N, Ndounga-Diakou LA, Entz-Werle N, Ducassou S, André N, **Sevrin F**, Chastagner P, Puiseux C, Cleirec M, Plantaz D, De Carli E, Gambart M, Khanfar C, Thouvenin S, Petit A, Klein S, Briandet C, Millot F, Pluchart C, Reguerre Y, Schneider P, Serre J, Halfon-Domenech C, Carausu L, Pigué C, Saumet L, Benadiba J, Abbou S, Laghouati S, Georger B, Vassal G. Centralized Investigator Review of Radiological and Functional Imaging Reports in Real-World Oncology Studies: The SACHA-France Experience. *Pediatr Blood Cancer* 2025; 72: e31449.

IF : 2.3. Catégorie C

Borovkov A, Assy J, Aerts I, Bourdeaut F, Cordero C, Laurence V, Leruste A, Winter S, Michon J, Orbach D, Pacquement H, Philippe-Chomette P, Pierron G, Masliah-Planchon J, Helfre S, Janoueix-Lerosey I, **Defachelles AS**, Pasqualini C, Jehanno N, Cyrta J, Gauthier A, Mosseri V, Doz F, Sarnacki S, Cardoen L, Brisse HJ, Luporsi M, Schleiermacher G. Atypical Neuroblastoma With Absent Urinary Catecholamine Excretion and 123I-mIBG Avidity Are of Favorable Outcome: A Retrospective French Single-Center Study. *Pediatr Blood Cancer* 2025; 72: e32025.

IF : 2.3. Catégorie C

Borovkov A, Orbach D, Bonneau-Lagacherie J, Carausu L, Guimard G, Haouy S, Jannier S, Pagnier A, Proust S, Verite C, Castex MP,

Reguerre Y, Blouin P, Mansuy L, Métayer L, Corradini N, **Defachelles AS**, Boutroux H. Desmoid-Type Fibromatosis Tumors in Children After First-Line Failure: Clinical Aspects and Approaches for Subsequent Therapeutic Lines. *Pediatr Blood Cancer* 2025; 72: e31866.

IF : 2.3. Catégorie C

Godard F, Haffreingue A, Hameury F, Sarnacki S, Hervieux E, Bonnard A, Guérin F, Rouger J, Brouard J, Vérité C, Ollivier M, Schmitt F, Scalabre A, Gambart M, Hunault MA, **Sudour-Bonnange H**, Buisson P, André N, Thebaud E, Habonimana E, Mansuy L, Marie-Cardine A, Lejeune J, Piolat C, Briandet C, Orbach D, Fresneau B, Reguerre Y, Mallebranche C, Rod J, Delehay F. Pulmonary Consequences of Surgical Treatment in Children's Primary Lung Tumors: A National Retrospective Study. *Pediatr Blood Cancer* 2025; 72: e31522.

IF : 2.3. Catégorie C

Groenendijk A, van Tinteren H, de Krijger RR, Vujanic G, Al-Saadi R, Pritchard-Jones K, Ramírez-Villar GL, Melchior P, Godzinski J, Schenk JP, Graf N, Segers H, **Sudour-Bonnange H**, Verschuur AC, Drost J, Perotti D, Al-Jilaihawi S, Brok J, van den Heuvel-Eibrink MM, Spreafico F, Mavinkurve-Groothuis AMC. Outcome of patients with a first relapse after intermediate- or high-risk Wilms tumor, treated according to SIOP WT 2001/UK-IMPORT study; A report from the SIOP renal tumor study group. *Urol Oncol* 2025; 43: 525.e19-525.e32.

IF : 2.3. Catégorie C

Hadjean E, Carton M, Couloigner V, Luscan R, Van Den Abbeele T, Teissier N, Faure-Contier C, Fresneau B, Morcrette G, Lacour B, Clavel J, Desandes E, Mallebranche C, Mondain M, Carausu L, Fayoux P, Dumesnil C, Boulanger C, Vérité C, Landman-Parker J, **Sudour-Bonnange H**, Marianowski R, Leboulanger N, Plantaz D, Ayari S, Akkari M, Sagardoy T, Calmels MN, Orbach D. Pediatric Head and Neck Germ Cell Tumors: Current Management and Risk of Malignant Transformation. *Pediatr Blood Cancer* 2025; 72: e31747.

IF : 2.3. Catégorie C

Pasqualini C, Proust S, Schleiermacher G, Gambart M, Jannier S, Petit A, Dupraz C, Thebaud E, Reguerre Y, Ndounga-Diakou LA, Laghouat S, **Defachelles AS**, Berlanga P. Chemo-Immunotherapy Rescue for High-Risk Neuroblastoma Patients With Progressive Disease Before High-Dose Chemotherapy: Real-World Data From the SACHA-France Study. *Pediatr Blood Cancer* 2025; 72: e32080.

IF : 2.3. Catégorie C

Poiree M, Gofti-Laroche L, Riberon C, Leblond P, Laurence V, Gaspar N, **Cordoba A, Lervat C**, Maréc-Berard P. A Review of GO-AJA's Impact on Adolescents and Young Adults with Cancer in France: A Decade of Progress and Challenges. *J Adolesc Young Adult Oncol* 2025; 14: 194-199.

IF : 1.2. Catégorie E

Caton L, Duprez C, Flahault C, **Lervat C**, Antoine P, Calvez A, Lamore K. A Qualitative Study on the Transition from Pediatric to Adult Care in Oncology: How Health Care Professionals Can Adapt Their Practice? *J Adolesc Young Adult Oncol* 2025; 14: 43-52.

IF : 1.2. Catégorie E

Roussel A, Léglise C, Rialland F, Duplan M, Falaque F, Boulanger C, Cardine AM, Alimi A, Pochon C, Rabian F, Hautefeuille C, Corbel A, Dupraz C, **Lervat C**, Alby-Laurent F. [Vaccination of children and adolescents treated for acute leukemia excluding HSCT recipients: Recommendations of the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE)]. *Bull Cancer* 2025; 112: 208-224.

IF : 0.8. Catégorie E

Berlanga P, Pasqualini C, Gambart M, Dumont B, Thebaud E, Tandonnet J, Benadiba J, Leruste A, Coze C, Schleiermacher G, **Defachelles AS**. Recommandations du Comité neuroblastome de la Société française de lutte contre les cancers et les leucémies de l'enfant et de l'adolescent pour la prise en charge des patients présentant un neuroblastome de haut risque en rechute/progression [Treatment guidelines for patients with relapsed/progressive high-risk neuroblastoma from the Neuroblastoma Committee of the French Society of Pediatric Oncology]. *Bull Cancer* 2025; 112: 1035-1044.

IF : 0.8. Catégorie E

Sudour-Bonnange H, Audry G, Ducou Le Pointe H, Coulomb A, Verschuur A, Thebaud E, Schleiermacher G, Dumont B, Jouglar E, Irtan S. Establishing a national multidisciplinary board for complex pediatric renal tumors: Lessons learned. *Bull Cancer* 2025: S0007-4551(25)00512-0.

IF : 0.8. Catégorie E

Claude L, Helfre S, Corradini N, Gaspar N, Berlanga P, Saumet L, Marec-Bérard P, **Lervat C**, Ropars M, Piperno-Neumann S, Boudou-Roquette P, Revon-Rivière G, Ducassou A, Martin V; pour le GroupOs français. Radiothérapie des sarcomes d'Ewing [Radiotherapy in Ewing sarcomas]. *Bull Cancer* 2025;112:656-663.

IF : 0.8. Catégorie E

Julieron M, Gomez-Mascard A, Vérité C, Toulmonde M, **Lervat C**, Kind M, Thariat J. Recommandations pour la prise en charge des ostéosarcomes de la mandibule de l'enfant, l'adolescent et l'adulte [Recommendations from the group of bone tumors of the French Childhood Cancer Society and the French Sarcoma Group/Group for the Study of Bone Tumors]. *Bull Cancer*. 2025 Jun;112(6):574-591.

IF : 0.8. Catégorie E

Pharmacie

Schwartz V, de Jorna R, Quintard A, Lester MA, Pinturaud M, Cormier N, D'Huart E, Fougereau E, Carvalho M, Sourisseau B, Gueneau P, Wasiak M, Jouvance A, Paul M, Chevrier R, Pourroy B, **Cazin JL**, Ranchon F, Madelaine-Chambrin I, Rioufol C. The French Experience of Pharmacists and CAR T-Cells: A Study of the French Society of Oncology Pharmacy (SFPO). *Hematol Oncol* 2025; 43: e70144.

IF : 3.9. Catégorie B

Barreau P, Feutry F, Abelé M, Villain A, Sakji I, Marliot G. Transportation of protein drugs at hospital: Comparison of mechanical stress occurring during pneumatic transportation and hand-carried transport. *J Pharm Sci* 2025; 114: 103715.

IF : 3.8. Catégorie C

Richard C, Carton M, Hazkani I, Couloigner V, Sheyn A, Rastatter J, Haroun L, Helmig S, Houston MB, Helfre S, **Thebault E**, Andre N, Faure Conter C, Teissier N, Fresneau B, Orbach D. Cervical Lymph Node Invasion in Pediatric Salivary Gland Malignancies: Clinical Overview and Therapeutic Implications. *Pediatr Blood Cancer* 2025; 72: e31581.

IF : 2.3. Catégorie C

Ranchon F, Huot L, Bardin C, Madelaine I, **Cazin JL**, Pourroy B, Tilleul P, Lemare F, Rioufol C. Randomised controlled trial to assess the impact of hospital-community pharmaceutical care on drug-related problems in oncology practice for at-risk outpatients treated with oral anticancer drugs-a French Society for Oncology Pharmacy (SFPO) study: DROP-SFPO study protocol. *BMJ Open* 2025; 15: e094825.

IF : 2.3. Catégorie C

Ranchon F, Slimano F, Borget I, Boulin M, Bardin C, Coliat P, Cormier N, Devys C, Fanciullino R, Paul M, Puisset F, Rioufol C, Tortolano L, Tournamille JF, Vigneron J, Chevrier R, Pourroy B, **Cazin JL**. Oncology pharmacy practice: Key insights, challenges, and perspectives - A position paper from the French Society for Oncology Pharmacy (SFPO). *Ann Pharm Fr* 2025; 83: 1040-1052.

IF : 1.1. Catégorie E

Strobbe G, Jeanjacquot M, Potey C, Carnot A, Marliot G. Grade 3 cytotoxicity in a patient with metastatic colorectal cancer consuming a mushroom powder-based alternative therapy. *J Oncol Pharm Pract* 2025; 31: 329-335.

IF : 0.9. Catégorie E

Poutrain E, Abelé-Naveau M, Baltora M, Villain A, Sakji I, Strobbe G, Marliot G. Securing the oral and enteral oncopediatric chemotherapy process in pediatric oncology: Introduction of the ENFit® standard in a controlled-atmosphere area and implementation of a dispensing service of medications to outpatients circuit with advice on proper use. *J Oncol Pharm Pract* 2025; 31: 422-429.

IF : 0.9. Catégorie E

Pneumologie

Remon J, Bironzo P, Girard N, Bigay-Game L, Juan-Vidal O, de Castro J, Reguart N, Greillier L, Cousin S, **Dansin E**, Majem M, Bernabé R, Mosquera Martinez J, Díaz M, Meza A, Alcalá-López D, García-Sanz A, Righi L, Novello S, Besse B. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. *Lancet Oncol* 2025; 26: 1215-1226.

IF : 35.9. Catégorie A

Amrane K, Cabarro B, Justeau G, Schneider S, Quantin X, Falchero L, Bigot F, Ferrari V, Guisier F, Girard N, Lena H, **Dansin E**, Madroszyk A, Bizieux A, Debievre D, Perol M, Simoneau Y, Bosquet L, Descourt R, Chouaïd C. Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis. *ESMO Open*. 2025; 10: 105343.

IF : 8.3. Catégorie B

Radiothérapie, Radiophysique

Vaugier L, Morvan C, **Pasquier D**, Buthaud X, Magné N, Beckendorf V, Sargos P, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Paul J, Blanc-Lapierre A, Supiot S. Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07). *Eur Urol* 2025; 87: 73-76.

IF : 25.2. Catégorie A

Biau J, Sun X, **Liem X**, Faivre JC, Eker E, Blanchard P, Tao Y, Doré M, Maingon P, Vulquin N, Alfonsi M, Thureau S, Huguet F, Racadot S, Thivat E, Molnar I, Boisselier P, Guihard S, Gallocher O, Dupin C, Batard S, Bourhis J, Lapeyre M. Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial. *JAMA Netw Open* 2025; 8: e2549975.

IF : 9.7. Catégorie A

Abancourt L, Ali M, Quivrin M, **Wallet J**, Schick U, Ingrosso G, Supiot S, Franzese C, Scorsetti M, Kerkmeijer L, Fodor A, Muzio ND, Jousset N, Boissier T, Detti B, Nicosia L, Alongi F, Trippa F, Leleu T, Dessoude L, Terlizzi M, Blanchard P, Scher N, Toledano A, Baude J, **Lartigau É**, **Barthoulot M**, Siva S, **Pasquier D**. Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series. *Eur Urol Oncol* 2025; 8: 774-781.

IF : 9.3. Catégorie A

Carsuzaa F, Favier V, Seguin L, Turri-Zanoni M, Camarda AM, Verillaud B, Herman P, Borsetto D, Schreiber A, Taboni S, Rampinelli V, Vinciguerra A, Vural A, **Liem X**, Busato F, Renard S, Dupin C, Doré M, Graff P, Tao Y, Racadot S, Moya Plana A, Landis BN, Marcy PY, Patron V, de Gabory L, Orlandi E, Ferrari M, Thariat J. Consensus for a postoperative atlas of sinonasal substructures from a modified Delphi study to guide radiotherapy in sinonasal malignancies. *Radiother Oncol* 2025; 206: 110784.

IF : 9.1. Catégorie A

Vera P, Giraud P, Hapdey S, Gouel P, Jan O, Le Roux P, Langlais A, Lévêque E, **Le Tinier F**, Olivier A, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boisselier P, Guillemard S, Salem N, Brenot-Rossi I, Garcia C, Berthold C, Giroux-Leprieur E, Moreau D, Guillermin S, Benali K, Tessonier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Loo M, Larrouy A, Ghazdar N, Chaumet-Riffaud P, Amour E, Zalcman G, Modzelewski R, Thureau S. Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Non-small Cell Lung Cancer. *J Nucl Med* 2025; 66: 516-524.

IF : 9.1. Catégorie A

Ka K, **Cordoba A**, Schiappa R, Martz N, Espenel S, Escande A, Demogeot N, Hannoun-Levi JM, Chargari C. Oncological Outcomes and Organ Preservation After Brachytherapy for Penile Carcinoma: A Multicentric Retrospective Study by the Brachytherapy Group of the French Society for Radiation Oncology. *Int J Radiat Oncol Biol Phys* 2025; 123: 1269-1276.

IF : 6.5. Catégorie A

Belkacemi Y, Debbi K, To NH, Tour RP, Quero L, Balsat M, Martel-Lafay I, Beauvais D, **Mirabel X**, Forcade E, Batard S, Devillier R, Gonzague-Casabianca L, Chevallier P, Guimas V, Brissot E, Maertens J, Poiré X, Ceballos P, Llorente CC, Bilger K, Bulabois CE, Cherif AM, Coraggio G, Quoc SN, Robin M, Loganadane G. Total Body Irradiation-Based Versus Chemotherapy-Alone Myeloablative Conditioning Regimen Before Hematopoietic Allogeneic Stem Cell Transplantation in Adults With Acute Lymphoblastic Leukemia: A Multi-Institutional Study From the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). *Int J Radiat Oncol Biol Phys* 2025; S0360-3016(25)06389-8.

IF : 6.5. Catégorie A

Le Guevelou J, Cuccia F, Flippot R, Ferrera G, Terlizzi M, Zilli T, De Crevoisier R, Hannoun-Levi JM, Supiot S, Sargos P, **Pasquier D**. The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer. *Prostate Cancer Prostatic Dis* 2025; 28: 546-556.

IF : 5.8. Catégorie A

Doyen J, Domp Martin A, Cruzel C, Stefan D, Arnault JP, Coutte A, icard-Gauci A, Mansard S, Gleyzolle B, Fontas E, Long-Mira E, **Mirabel X**, Mortier L, Montaudie H. Nivolumab and ypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial. *Eur J Cancer* 2025; 217: 115256.

IF : 7.1. Catégorie B

Giraud P, Guihard S, Thureau S, Guilbert P, Ruffier A, Eugene R, Lamrani-Ghaoui A, Chargari C, **Liem X**, Bibault JE. Prediction of the need of enteral nutrition during radiation therapy for head and neck cancers. *Radiother Oncol* 2025; 203: 110693.

IF : 5.3. Catégorie B

Brion T, Ghodssighassemabadi R, Auzac G, Kirova Y, Racadot S, Benchalal M, Clavier JB, Brunaud C, Fouche-Chand ME, Argo-Leignel D, Peignaux-Casasnovas K, Benyoucef A, **Pasquier D**, Guilbert P, Blanchecotte J, Tallet-Richard A, Lamrani A, Bergeau M, Bielynite G, Ruffier A, Karamouza E, Michiels S, Rivera S. Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial. *Radiother Oncol* 2025; 207: 110849.

IF : 5.3. Catégorie B

Gobbini E, Diallo MH, **Pasquier D**, Schneider S, Chouaid C, Debievre D, Quantin X, Gervais R, Valette CA, Justeau G, Ravoire M, Madroszyk A, Pichon E, Falchero L, Simoneau Y, Bylicki O, Baranzelli A, Bosquet L, Pérol M, Girard N. Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. *Lung Cancer* 2025; 202: 108499.

IF : 4.4. Catégorie B

Cotte E, Arquilliere J, Artru P, Bachet JB, Benhaim L, Bibeau F, Hristou N, Conroy T, Doyen J, Hoeffel C, Meillan N, **Mirabel X**, Pioche M, Rivin Del Campo E, Vendrely V, Huguet F, Bouché O; Thésaurus National de Cancérologie Digestive (TNCD) (Société Nationale Française de Gastroentérologie (SNFGE); Fédération Francophone de Cancérologie Digestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Société Française de Chirurgie Digestive (SFCD); Société Française d'Endoscopie Digestive (SFED); Société Française de Radiothérapie Oncologique (SFRO); Association de Chirurgie Hépatobiliaire-Pancréatique et Transplantation (ACHBT); Société Française de Pathologie (SFP); Réseau National de

Référence des Tumeurs Rares du Péritoine (RENAPE); Société Nationale Française de Colo-Proctologie (SNFCP); Association Française pour l'Étude du Foie (AFEF); Société Française de Radiologie (SFR)); GRECCAR (Groupe de Recherche Chirurgical sur la Cancer du Rectum). Rectal cancer - French intergroup clinical practice guidelines for diagnosis treatment and follow-up (TNCD SNFGE FFCD GERCOR UNICANCER SFCD SFED SFRO ACHBT SFP RENAPE SNFCP AFEF SFR and GRECCAR). Dig Liver Dis 2025; 57: 669-679.

IF : 3.8. Catégorie C

Crop F, Bocquet M, Kirie C, Laffarguette J, Cayez R, Ladjimi MT, Rault E, Comte P, Vanquin L, Lacornerie T, Decoene C. Accuracy of manufacturer integrated quality control for helical radiotherapy. Phys Imaging Radiat Oncol 2025; 34: 100750.

IF : 3.3. Catégorie B

Pozin J, Bhandari M, Valle L, Nickols NG, Kishan AU, Kamran SC, Baumann B, Efstathiou JA, Crook J, **Pasquier D**, Liauw SL, Harkenrider MM, Solanki AA. The Evolving Management of Radiorecurrent Prostate Cancer. Semin Radiat Oncol 2025; 35: 450-462.

IF : 3.2. Catégorie B

Cozzi S, Lazrek A, Rubini G, Rubini D, Sardaro A, Houabes S, **Laude C**, Gassa F, Bardoscia L, Roukoz C. Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead? Cancers (Basel) 2025;17:1176.

IF : 4.4. Catégorie C

Lazrek A, Finocchi Gheri S, Petre A, Houabes S, Serre AA, Gassa F, Sandt M, **Laude C**, Roukoz C, Cozzi S. Case report of the first use of a hydrogel rectal spacer for prostate cancer reirradiation via LDR brachytherapy: applications and technical notes. Front Oncol 2025;15:1494304.

IF : 3.3. Catégorie C

Fessi Z, Bonnier S, Lodyga K, Wallet J, Barthoulot M, Delerue C, Lemoine P, Archer P, Dworczak M, Pasquier D. Stereotactic re-irradiation for lymph node recurrence of breast cancer. BMC Cancer 2025; 26: 70.

IF : 3.4. Catégorie C

Chen Y, **Pasquier D**, Verstappen D, Woodruff HC, Lambin P. An interpretable ensemble model combining handcrafted radiomics and deep learning for predicting the overall survival of hepatocellular carcinoma patients after stereotactic body radiation therapy. J Cancer Res Clin Oncol 2025; 151: 84.

IF : 2.8. Catégorie C

Mortier L, **Mirabel X**. Radiotherapy and skin cancers - An essential collaboration for onco-dermatology. Ann Dermatol Venereol 2025; 152: 103359.

IF : 2.8. Catégorie C

Cayez R, Lacornerie T, Risbourg S, Lodyga K, Ba A, Crop F. Multi-criteria optimization for comparing free-breathing and breath-hold techniques in helical and volumetric treatment of locoregional left-sided breast cancer. Phys Med 2025; 138: 105175.

IF : 2.7. Catégorie C

Beldjoudi G, Goudjil F, Lafond C, Raucoules S, Moignier C, Maneval D, Bartau C, Hangard G, Trauchessec D, Anthonipillai V, Gehin W, **Lacornerie T**, Claude L, Ollivier L. Dose escalation in pediatric pelvic Ewing's Sarcoma: Insights from a national treatment planning exercise. Phys Med 2025; 137: 105063.

IF : 2.7. Catégorie C

Guévelou JL, Sargos P, Ost P, Alongi F, Arcangeli S, Berlin A, Blanchard P, Bruynzeel A, Chapet O, Dal Pra A, Dess RT, Guckenberger M, Loblaw A, Kishan AU, Jereczek-Fossa B, **Pasquier D**, Shelan M, Siva S, Tree AC, Zamboglou C, Supiot S, Murthy V, Zilli T. Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey. Clin Transl Radiat Oncol 2025; 51: 100907.

IF : 2.7. Catégorie C

Le Tourneau C, Takácsi-Nagy Z, Nuyts S, Thureau S, Liu F, Hoffmann C, Hackman TG, Lesnik M, Debarb A, Finzi L, Devisetty K, Vivar OI, Farber LA, Nguyen F, **Liem X**, Natelaouri E, Psyrris A, Burian M, Yu J, Yom SS. Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC. Future Oncol 2025 ;21: 1489-1499.

IF : 2.6. Catégorie D

Lebret D, Lafond C, Leseur J, Barateau A, Chan Sock Line D, Peignaux K, Mesgouez-Nebout N, Le Blanc-Onfroy M, Hanzen C, Allouache N, Renard-Oldrini S, **Le Tinier F**, De Crevoisier R, Simon A. Prospective multi-institutional study of library-based adaptive radiotherapy for cervical cancer: Evaluation of plan-of-the-day selection and population analysis. J Appl Clin Med Phys 2025; 26: e70356.

IF : 2.2. Catégorie C

Virbel G, Ka K, Escande A, Mortier L, **Barthoulot M, Liem X, Mirabel X, Lartigau EF, Cordoba A.** HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients. Brachytherapy 2025; 24: 799-806.

IF : 1.8. Catégorie D

Zhou Y, Escande A, Beddok A, Chargari C, Sunyach MP, Ayadi M, Khalifa J, Antoni D, Cao K, **Pasquier D**, Hannoun-Lévi JM, Langé M, Faivre JC, Thureau S, Supiot S. Reirradiation of lung breast and bone tumours suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique. Cancer Radiother 2025; 29: 104780.

IF : 1.4. Catégorie D

Latorzeff I, Camps-Maléa A, Hennequin C, Chapet O, **Pasquier D**, Créhange G, Pommiet P, de Crevoisier R, Blanchard P, Schicke U, Marchesi V, Sargos P, Supiot S. External beam radiotherapy for prostatic cancers: 2025 update. Cancer Radiother 2025; 29: 104777.

IF : 1.4. Catégorie D

Bayart É, Benderitter M, Boussin F, Balosso J, Deutsch É, Cohen Jonathan-Moyal É, **Lacornerie T**, Pinel S, Prezado Y, Robert C, Supiot S, Delpon G, Bourcier C. RadioTransNet: Preclinical research network coordinated by the Société française de radiothérapie oncologique and Société française de physique médicale, 2025 update. Cancer Radiother 2025; 29: 104764.

IF : 1.4. Catégorie D

Zhou Y, Escande A, **Pasquier D**, Chargari C, Ayadi M, Khalifa J, Antoni D, Latorzeff I, Guimas V, Vendrely V, Beddok A, Supiot S. Reirradiation of prostate gynaecologic and pelvic tumours suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique. Cancer Radiother 2025; 29: 104778.

IF : 1.4. Catégorie D

Ghannam Y, Le Scodan R, Rivera S, Kirova Y, **Pasquier D**, Hennequin C, Bourcier C, Cutuli B, Richard-Tallet A. Radiotherapy of breast cancer: 2025 update. Cancer Radiother 2025; 29: 104767.

IF : 1.4. Catégorie D

Chargari C, Ducassou A, Laville A, Lucia F, Petit A, Flandin I, **Cordoba A**, Renard S, Demontoy S, Hannoun-Lévi JM, Lafond C, Escande A. Radiotherapy and brachytherapy for cervical cancer: Recommendations of the Société française de radiothérapie oncologique. Cancer Radiother 2025; 29: 104753.

IF : 1.4. Catégorie D

Chargari C, Ducassou A, Leblanc J, Lucia F, Petit A, Flandin I, **Cordoba A**, Lafond C, Renard S, Escande A. Radiotherapy for endometrial cancer: 2025 update. Cancer Radiother 2025; 29: 104752.

IF : 1.4. Catégorie D

Chargari C, Ducassou A, Roukoz C, Lucia F, Petit A, **Cordoba A**, Lafond C, Renard S, Escande A. Role of radiotherapy in the treatment of primary vaginal cancer: Recommendations of the Société française de radiothérapie oncologique 2025; update. Cancer Radiother 2025; 29: 104725.

IF : 1.4. Catégorie D

Chargari C, Renard S, Ossedat MA, **Cordoba A**, Lucia F, Petit A, Cordoba A, Lafond C, Renard S, Escande A. Role of radiotherapy in the management of vulvar cancer: Recommendations of the Société française de radiothérapie oncologique, 2025 update. Cancer Radiother 2025; 29: 104726.

IF : 1.4. Catégorie D

Allali S, Loap P, Shrebati A, **Lacornerie T**, Kirova Y, Sebag F, Cao KI. Radiotherapy for patients with pacemakers and implantable cardioverter defibrillators: A review of the recommendations and practical application. Cancer Radiother 2025; 29: 104717.

IF : 1.4. Catégorie D

Shrebati A, Le Fèvre C, **Lacornerie T**, Noël G, Antoni D, Loap P, Kirova Y. Management of metallic implants in radiotherapy: 2025 update. Cancer Radiother 2025; 29: 104723.

IF : 1.4. Catégorie D

Benziane-Ouaritini N, Le Guevelou J, Supiot S, Terlizzi M, Chapet O, Ouzaid I, **Pasquier D**, Marchesi V, Latorzeff I, Sargos P. Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO the French society for radiation oncology). Cancer Radiother 2025; 29: 104713.

IF : 1.4. Catégorie D

Antoni D, Schick U, Jarnet D, Josset S, Mazurier J, Parent L, **Pasquier D**, **Lacornerie T**. Stereotactic radiotherapy for lung cancer: Influence of prescription modality on clinical outcome. Cancer Radiother 2025; 29: 104710.

IF : 1.4. Catégorie D

Schick U, Antoni D, Josset S, **Lacornerie T**, Mazurier J, Parent L, **Pasquier D**. Stereotactic radiotherapy for prostate cancer. Cancer Radiother 2025; 29: 104709.

IF : 1.4. Catégorie D

Hibon J, Waissi W, **Pasquier D**, Racadot S. Breast cancer tumour board: Which patients are eligible for radiotherapy de-escalation or omission? *Cancer Radiother* 2025; 29: 104688.

IF : 1.4. Catégorie D

Giraud N, Ortholan C, Quivrin M, Andraud M, **Cordoba A**, Shaffer R, Chargari C, Leroy T. Radiotherapy: Beyond cancer... *Cancer Radiother* 2025; 29: 104682.

IF : 1.4. Catégorie D

Lahmi L, Bibault JE, Constantinides Y, Azria J, **Cheval V**, Dejean C, Durdux C, Ducteil A, Escande A, Gesbert C, Haaser T, Kobeissi G, Lemanski C, Nataf M, Raynaud C, Thureau S, Lagrange JL, Huguet F; Commission éthique de la Société française de radiothérapie oncologique (SFRO). [An ethical approach to the integration of artificial intelligence in radiation oncology]. *Cancer Radiother* 2025; 29: 104673.

IF : 1.4. Catégorie D

Carcopino X, Ouldamer L, Huchon C, Asseeva P, Azaïs H, Bendifallah S, Brun JL, Canlorbe G, Chargari C, Chauvet P, **Cordoba A**, Courcier H, Dabi Y, de Berti M, Diguisto C, Gaillard T, Gauthier T, Gertych W, Gladieff L, Graesslin O, Kerbage Y, Koskas M, Laas E, Lacorre A, Lavoué V, Lecointre L, Lecuru F, Marguerite F, Martinez A, Maternowski PJ, Mathevet P, Menouer I, Mimoun C, Larnaudie A, Ghannam Y, El Houat Y, Michalet M, Huguet F, Camps-Maléa A, Faivre JC, Pointreau Y, Leroy T, Escande A, Lesueur P, Thureau S, Raynaud C, Latorzeff I, **Liem X**, Blanchard P, Rivera S, Bibault JE, Tolédano A, Janoray G, Lafond C, Ollivier L. Evolution of radiation oncology training in France: Over 20 years of the role of the Société française des jeunes radiothérapeutes oncologues (SFJRO the French society of young radiation oncologists). *Cancer Radiother* 2025; 29: 104620.

IF : 1.4. Catégorie D

Beudelot C, Delgrange V, Coutte A, **Bimbai AM**, **Le Deley MC**, **Rault E**, **Mirabel X**, **Lartigau ÉF**, **Pasquier D**, **Mouttet-Audouard R**. Extra- and intracranial schwannomas treated with fractionated stereotactic irradiation: Results of a retrospective multicentric study. *Cancer Radiother* 2025; 29: 104621.

IF : 1.4. Catégorie D

Cravéreau O, Bourbonne V, Vaugier L, Lucia F, **Le Tinier F**, Cadranell J, Duchemann B, Habert P, Martz N, Gehin W, Bruand M, Stefani A, Marcel J, Trampetti I, Clément-Duchêne C, Lerouge D, Laville A, Cao K, Pourel N, Zaccariotto A, Bellière-Calendry A, Thillays F, Tanguy R, Antoni D, Girard N, Martin É, Godbert B, Nakad A, Treffel G, Massin M, Charzat V, Thureau S, Lapierre A, Faivre JC. Recommandations de l'Association francophone pour les soins oncologiques de support et de la Société française de radiothérapie oncologique relatives aux effets secondaires respiratoires radio-induits [Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique]. *Cancer Radiother* 2025; 29: 104687.

IF : 1.4. Catégorie D

Larnaudie A, Ghannam Y, El Houat Y, Michalet M, Huguet F, Camps-Maléa A, Faivre JC, Pointreau Y, Leroy T, Escande A, Lesueur P, Thureau S, Raynaud C, Latorzeff I, **Liem X**, Blanchard P, Rivera S, Bibault JE, Tolédano A, Janoray G, Lafond C, Ollivier L. Evolution of radiation oncology training in France: Over 20 years of the role of the Société française des jeunes radiothérapeutes oncologues (SFJRO, the French society of young radiation oncologists). *Cancer Radiother* 2025;29:104620.

IF : 1.4. Catégorie D

Levy A, **Tonneau M**, Darréon J, Khalifa J, Antoni D, Blais E, Le Péchoux C, Lerouge D, Lucia F, Marguerit A, Martin É, Pichon B, Pourel N, Riet FG, Giraud P, Thureau S. Radiotherapy for lung metastases. *Cancer Radiother* 2025; 29: 104760.

IF : 1.4. Catégorie D

Moureau A, Netter A, Philip CA, Rousset P, Sanson C, Thomassin I, Touboul C, Levêque J. [Cervical cancer: Guidelines for clinical practice]. *Gynecol Obstet Fertil Senol* 2025; 53: 365-489.

IF : 0.8. Catégorie E

Beddok A, Willmann J, Embring A, Appelt AL, Balermipas P, Chua K, Choi JI, Elger BS, Gabrys D, Hoskin P, Niyazi M, **Pasquier D**, Paradis K, Kaidar-Person O, Plaisier C, Schmitt NC, Steuer CE, Thariat J, Yom SS, Poortmans P, Vasquez Osorio E, Andratschke N. Reirradiation: Standards challenges and patient-focused strategies across tumor types. *CA Cancer J Clin* 2025; 75: 630-666.

IF : 0.8. Catégorie E

Sarcomes

Penel N, Italiano A, **Wallet J**, Chaigneau L, Verret B, Firmin N, Watson S, Valentin T, Bompas E, Bertucci F, Brahmi M, Henon C, Brunot A, Spalato-Ceruso M, **Vanseymortier M**, **Heyman-Decoupigny E**, **Ryckewaert T**, **Le Deley MC**, Perrin C, Blay JY. Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial. *Ann Oncol* 2025; 36: 944-953.

IF : 65.4. Catégorie A

Trédan O, Pouessel D, **Penel N**, Chabaud S, Gomez-Roca C, Delord JP, Pannier D, Brahmi M, Fabbro M, Garcia ME, Larrieu-Ciron D, Ray-Coquard I, Viala M, Italiano A, Tosi D, Cassier P, Dufresne A, Attignon V, Boyault S, Treilleux I, Viari A, Pérol D, Blay JY. Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial. *Nat Med* 2025; 31: 1502-1508.

IF : 50. Catégorie A

Marabelle A, O'Malley DM, Hendifar AE, Ascierto PA, Motola-Kuba D, **Penel N**, Cassier PA, Bariani G, De Jesus-Acosta A, Doi T, Longo F, Miller WH Jr, Oh DY, Gottfried M, Yao L, Jin F, Gozman A, Maio M. Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. *Nat Cancer* 2025; 6: 253-258.

IF : 28.5. Catégorie A

Blay JY, Toulmonde M, Valentin T, Firmin N, Watson S, Duffaud F, Bompas E, Rios M, Ropars M, Anract P, Dufresne A, Gantzer J, Le Nail LR, Saada E, Hervieu A, Bertucci F, Dubray-Longeras P, Crenn V, Perrin C, Soibinet P, Verret B, Italiano A, Decanter G, Ferron G, Carrere S, Bonvalot S, Brahmi M, Henon C, Spalato-Ceruso M, **Lebellec L**, Ducassou A, Colard-Thomas J, Piperno-Neumann S, Mattei JC, Gouin F, Faron M, **Ryckewaert T**, Meeus P, Honoré C, Le Loarer F, Coindre JM, Ngo C, Meurgey A, Karanian M, Chemin-Airiau C, Ducimetiere F, Morelle M, **Penel N**, Le Cesne A. Clinical presentation management and outcome of 11132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry. *Lancet Reg Health Eur* 2025; 57: 101403.

IF : 13. Catégorie A

Colombo C, Hakkesteegt S, Le Cesne A, Barretta F, Blay JY, Grünhagen DJ, **Penel N**, Lam L, Fiore M, Palassini E, Grignani G, Tolomeo F, Collini P, Merlini A, Perrone F, Stacchiotti S, Verhoef C; Dutch Grafiti Group; Bonvalot S; French Sarcoma Group; Gronchi A. Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational Studies. *Clin Cancer Res* 2025; 31: 603-610.

IF : 10.2. Catégorie A

Ferraioli D, Borella F, Meurer M, Lebreton C, **Penel N**, Bertucci F, Bompas E, Italiano A, Firmin N, Bertero L, Peyrottes I, Mancini J, Isambert N, Chevreau C, Ferron G, Perrin C, Piperno-Neumann S, Cosma S, Pautier P, Loaec C, Aust S, Chopin N, Meeus P, Blay JY, Gonin J, Duffaud F, Colombo PE, Ray-Coquard I. Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SARcoma Management - OSAMA Study). *Int J Gynecol Cancer* 2025; 35: 101692.

IF : 4.7. Catégorie A

Rethouze F, Risbourg S, Schiffler C, Chabaud S, **de Courrèges A, Le Deley MC**, Blay JY, **Feutry F**, Jimenez M, **Vanseymortier M, Penel N**, Duffaud F, **Lebellec L**. COREGO: drug-drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials. *ESMO Open* 2025; 10: 105117.

IF : 8.3. Catégorie B

Cuvelier C, Brahmi M, Sobhani I, Verret B, Grancher A, **Penel N**, Toulmonde M, Lahlou W, Dupuis H, Calavas L, Muller M, Watson S, Bruyat D, Poumeaud F, Chaigneau L, Manfredi S, Lecomte T, Bertucci F, Ghiringhelli F, Pracht M, Mourthadhoi F, Monceau-Baroux L, Helyon M, Kurtz JE, Roquin G, Regenet N, Vinches M, Tougeron D, Wolkenstein P, Blay JY, Bouche O, Hautefeuille V. Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC. *ESMO Open* 2025; 10: 104477.

IF : 8.3. Catégorie B

Fazel M, Varnier R, Vanacker H, **Penel N**, Watson S, Verret B, Valentin T, Bompas E, Waissi W, Meurgey A, Ducimetière F, Blay JY, Dufresne A, Brahmi M. Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC a French retrospective multicenter cohort study. *Cancer* 2025; 131: e70052.

IF : 7.1. Catégorie B

Bompas E, Campion L, Toulmonde M, Le Cesne A, Saint-Jean M, Lebbe C, Valentin T, Rios M, Duffaud F, Firmin N, Carrère S, Piperno-Neumann S, Perrin C, Ropars M, Bonvalot S, Watson S, Tzanis D, Boudou-Roquette P, Tlemsani C, de Percin S, Desmoulin I, Causeret S, Ducoulombier A, Saada-Bouid E, Bertucci F, Kurtz JE, Gantzer J, Brahmi M, Dufresne A, Gouin F, Meeus P, Italiano A, Michot A, Spatalo-Ceruso M, Verret B, Honoré C, **Ryckewaert T, Decanter G**, Mattei JC, Gangloff D, Salas S, Narciso B, Moreau-Bachelard C, Le Nail LR, Dubray-Longeras P, Fiorenza F, Chagneau L, Guillemet C, **Penel N**, Blay JY. Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database. *Eur J Cancer* 2025; 229: 115788.

IF : 7.1. Catégorie B

Poumeaud F, Valentin T, Fares N, Segier B, Watson S, Verret B, Tlemsani C, **Penel N**, Lejeune S, Firmin N, Sabouret A, Thery JC, Bonvalot S, Cottareau E, Cauchin E, Lancon A, Nambot S, Zattara H, Coudert M, Fourme E, Nogues C, Tougeron D, Prieur F, Collonge-Rame MA, Denis C, Laurent-Puig P, Chieze-Valero S, Dreyfus H, Jaffrelot M, Vande Perre P, Rochaix P, Gomez-Mascard A, Rochefort P, Campoy S, Chibon F, Lasset C, Selves J, Guimbaud R. Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy. *Eur J Cancer* 2025; 216: 115196.

IF : 7.1. Catégorie B

Penel N, Pautier P, Blay JY. Maintenance after first-line treatment for advanced soft tissue sarcoma. Crit Rev Oncol Hematol 2025; 216: 104959.

IF : 5.6. Catégorie B

Fazel M, Varnier R, Vanacker H, **Penel N**, Watson S, Verret B, Valentin T, Bompas E, Waissi W, Meurgey A, Ducimetière F, Blay JY, Dufresne A, Brahmi M. Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study. Cancer 2025; 131: e70052.

IF : 5.1. Catégorie B

Neuberg M, Bonvalot S, Faron M, **Decanter G**, Tzanis D, Varatharajah S, Meeus P, Fau M, Bouillin A, Delhorme JB, Causeret S, Marchal F, Wernert R, Carrere S, Honoré C. What is the primary cause of postoperative death after primary retroperitoneal sarcoma surgery in a high-volume center? A nationwide study by the French Sarcoma Group. Eur J Surg Oncol 2025; 51: 110003.

IF : 2.9. Catégorie B

Poitureau S, **Le Deley MC**, Brahmi M, Bompas E, Kurtz JE, Nannini S, Perrin C, **Lebellec L**, **Ryckewaert T**, **Ould-Ammar R**, **Leguillette C**, Blay JY, **Penel N**. Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas. Cancer Med 2025; 14: e71131

IF : 3.1. Catégorie C

Collaud S, Stork T, Adamkova D, Aigner C, Bravio I, Brunello A, Cerbone L, Clermidy H, De Cock L, Gasperoni S, Girard N, Mariuk-Jarema A, Lefering R, Melis E, Marquina G, Mazzeo F, Mykoliuk I, Pantaleo MA, **Penel N**, Schildhaus HU, Strippoli S, Vincenzi B, Watson S, Blay JY, Bauer S. Outcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective study. JTCVS Open 2025; 28: 565-573.

IF : 1.9. Catégorie C

Valentin T, **Penel N**, Toulmonde M. [Sarcoma: a plural entity]. Rev Prat 2025; 75: 954-958.

Catégorie NC

Sénologie

Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, Colleoni M, Kaczmarek E, Punie K, Song X, Armstrong A, Bianchi G, Stradella A, Ladoire S, Lim JSJ, Quenel-Tueux N, Tan TJ, Escrivá-de-Romaní S, O'Shaughnessy J; **TULIP Trial Investigators**. Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label Randomized Phase III Trial (TULIP). J Clin Oncol 2025; 43: 513-523.

IF : 43.4. Catégorie A

Ramtohul T, Lollivier D, Spriet J, Jin M, Djerroudi L, Gaillard T, Bonneau C, Loirat D, Bello-Roufai D, Kirova Y, Loap P, Malhaire C, Vincent Salomon A, Bidard FC, Tardivon A, **Maillez A**, Wallaert L, **Ceugnart L**, Nhy C, Cabel L. Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy. Radiology 2025; 316: e243824.

IF : 15.2. Catégorie A

Guiu S, Balmaña J, Lemerrier P, Follana P, Gonçalves A, Bigot F, Frenel JS, Brain E, **Maillez A**, Chakiba Brugere C, Curtit E, Derbel O, Dalenc F, Derquin F, Duhoux F, Canon JL, Pimentel I, Chevalier LM, Buisson A, Guyonneau C, Lemonnier J, Delalogue S, Bachelot T. Combination of Olaparib Durvalumab and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial. Clin Cancer Res 2025; 31: 4633-4643.

IF : 10.2. Catégorie A

Raft J, Dureau S, Fuzier R, Augé M, Lamotte AS, **Lemoine A**, Albi-Feldzer A. Erector spinae plane block versus paravertebral block for major oncological breast surgery: a multicentre randomised controlled trial. Br J Anaesth 2025; 135: 772-778.

IF : 9.2. Catégorie A

Albi-Feldzer A, Gayraud G, Dureau S, Augé M, **Lemoine A**, Raft J. Efficiency of interpectoral and pectoralis plane blocks for breast surgery: A randomized controlled trial. J Clin Anesth 2025; 103: 111805.

IF : 5.1. Catégorie A

Cherifi F, Cabel L, Bousrih C, Volant E, Dalenc F, Mery B, Auvray Kuentz M, **Maillez A**, Ladoire S, de Nonneville A, Alexandre M, Benistant L, Leheurteur M, Bailleux C, Debled M, Frenel JS, Loirat D, Bastien E, Aussedat Q, Bidard FC, Aho S, Glenet A, Mourato-Ribeiro J, Johnson A, Christy F, Emile G. PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer real-world French cohort. ESMO Open 2025; 10: 105907.

IF : 8.3. Catégorie B

Saint-Ghislain M, Chabaud S, Dalenc F, Allouache D, Cameron D, Martinez M, Grenier J, Barthelemy P, Brunt M, Kaluzinski L, Maillez A, Legouffe E, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Canon JL, Bliss J, Lemonnier J, Andre F, Bachelot T, Cottu P. Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial. ESMO Open 2025; 10: 105050.

IF : 8.3. Catégorie B

Varnier R, Pérol D, Jacot W, **Mailliez A**, Diéras V, Dalenc F, Gonçalves A, Levy C, Arnedos M, Frenel JS, Bailleux C, Massard V, Brain E, Sauterey B, Savoye AM, Bosquet L, Thery JC, Petit T, Bachelot T, Grinda T, Ray-Coquard I. Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort. ESMO Open 2025; 10: 105803.

IF : 8.3. Catégorie B

Pujol P, Roca L, Lortholary A, Lasset C, Crivelli L, Berthet P, Tennevet I, Petit T, Chabbert-Buffet N, Gesta P, Saule C, Chiesa J, Nguyen TD, **Mailliez A**, Callet NA, Noguès C, Dreyfus H, Delnatte C, Prieur F, Gladieff L, Ingster O, Galibert V, Lemonnier J, Delaloge S. Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study). Eur J Cancer 2025; 231: 116101.

IF : 7.1. Catégorie B

Decanter C, Dassonneville A, D'Orazio E, Behal H, **Gagez AL**, **Mailliez A**, Pigny P. AMH decline during chemotherapy reflects breast cancer cell DNA damage response (DDR) proficiency: the ONCO AMH1 pilot study. J Assist Reprod Genet 2025; 42: 1435-1441.

IF : 2.7. Catégorie B

Abahssain H, **Pasquier D**, Laabid K, Barani M, Borges S, Poitureau S, Bettache G, Nguyen TL, Bytha M, Rodriguez J, Lemaire A, Curigliano G, Souadka A. Modern Management of the Axilla in HER2-Negative Hormone Receptor-Positive Early Breast Cancer Upfront Surgery: Toward De-Escalation and Individualization. Cancers (Basel) 2025; 18.

IF : 4.4. Catégorie C

Kasprowicz A, Cavdarli S, Delannoy P, Le Guezennec X, Defebvre C, Spriet C, Jonckheere N, Le Doussal JM, Krzewinski-Recchi MA, Mitra S, **Meignan S**, Groux-Degroote S. Anti-OACGD2 antibody in combination with ceramide kinase inhibitor mediates potent antitumor cytotoxicity against breast cancer and diffuse intrinsic pontine glioma cells. Mol Cell Biochem 2025; 480: 2555-2571.

IF : 3.7. Catégorie C

Bécourt S, Abadie-Lacourtoisie S, Calvat T, Coudurier-Curveur I, Fiteni F, Mery B, Meynard G, Scotté F, Vaflard P, Zelek L. Management of cancer treatment-related fatigue in advanced breast cancer patients: an expert committee's opinion. Front Oncol. 2025 Oct 9;15:1617600.

IF : 3.3. Catégorie C

Spriet J, Miled AB, **Mailliez A**, **Bonnier S**, **Forestier A**, **Chauvet MP**, **Rozwag C**, **Aoud IE**, **Ceugnart L**. Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and performance of ultrafast sequences. Breast Cancer Res Treat 2025; 212: 195-203.

IF : 3. Catégorie C

Hego F, **Barthoulot M**, **Chretien S**, **Pierard C**, **Boulaire M**, **Bécourt S**, **Boulanger L**, **Ceugnart L**, **Conoy AL**, **Oca F**, **Mailliez A**. Breast Cancer Prognosis in Young BRCA1/BRCA2 Mutation Carriers: A Retrospective Hospital-based Cohort Study. Clin Oncol (R Coll Radiol) 2025; 37: 103658.

IF : 3. Catégorie C

Passildas J, Paillard MJ, Uwer L, Molnar I, Dohollou N, Petit T, **Hajjaji N**, Boudin L, Lorgis V, Jacquin JP, Abrial C, Mouret-Reynier MA. Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study. Cancer Epidemiol 2025; 96 102800.

IF : 2.3. Catégorie C

Raffo-Romero A, Ziane-Chaouche L, **Hajjaji N**, Salzert M, Duhamel M. Protocol for generating a co-culture of macrophages with breast cancer tumoroids. STAR Protoc 2025; 6: 103536.

IF : 1.3. Catégorie E

Bécourt S, **Cheymol C**, **Cren PY**, **Moultet-Audouard R**. [Brain metastases in breast cancer: Diagnosis and management]. Bull Cancer 2025; 112: 828-837.

David M, Jacquemin J, Drouet Y, Teyssier M, Heinemann M, Rossi L, Faure C, Klingler S, Chopin N, Lasset C, **Mesdag V**. Capsular rupture and axillary lymph node micrometastasis in breast cancer: Therapeutic and prognostic implications. Bull Cancer 2025; 112: 904-915.

IF : 0.8. Catégorie E

Assaf A, Forzy ML, Pétigny V, Poncelet E, **Ceugnart L**. Prévalence des calcifications artérielles mammaires chez les patientes concernées par le dépistage organisé du cancer du sein dans les Hauts-de-France [Prevalence of breast arterial calcification in women who underwent a breast cancer screening in the Hauts-de-France]. Bull Cancer 2025; 112: 695-701.

David M, Jacquemin J, Drouet Y, Teyssier M, Heinemann M, Rossi L, Faure C, Klingler S, Chopin N, Lasset C, **Mesdag V**. Capsular rupture and axillary lymph node micrometastasis in breast cancer: Therapeutic and prognostic implications. Bull Cancer 2025; 112: 904-915.

IF : 0.8. Catégorie E

Lardinois C, Bleret V, Danthine D, Lifrange É, Jerusalem G, Cusumano P. Biomarqueurs moléculaires dans le cancer du sein : avancées pour la pratique de la médecine de précision [Molecular biomarkers in breast cancer : advances in precision medicine]. Rev Med Liege 2025;80:42-47.

UMB

Adriana P, Carbonnier V, De Palma FDE, Perez-Lanzon M, Vergé V, Quivoron C, Lamant L, Brugieres L, Rigaud C, Ducassou S, Dourthe ME, **Le Deley MC**, Damm-Welk C, Woessmann W, Minard-Colin V, Maiuri MC, Kroemer G. Association of immune relevant single nucleotide polymorphisms with ALK-positive anaplastic large cell lymphoma presentation and outcome: results of the immuno ALCL study. J Transl Med 2025; 23: 1434.

IF : 7.5. Catégorie B

Rubio-San-Simón A, Wilson W, Sironi G, **le Deley MC**, Palmerini E, Gaspar N, Piperno-Neumann S, Hecker-Nolting S, Strauss S, van Ewijk R, Meazza C; FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 3 on recurrent/refractory osteosarcoma trials. Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review. Br J Cancer 2025; 133: 1020-1028.

IF : 6.8. Catégorie B

Pereira V, **Barthoulot M**, Aladjidi N, Contet A, Dalle JH, Dourthe MÉ, Garnier N, Bruno B, Leruste A, Pellier I, Simonin M, Paillard C, Verschuur A, Ducassou S, Lamant L, Brugieres L, **Le Deley MC**, Rigaud C. Outcome of childhood ALK-positive anaplastic large cell lymphoma relapses: Real-life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children. Pediatr Blood Cancer 2025; 72: e31397.

IF : 2.3. Catégorie C

Urologie

Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 2025; 406: 461-474.

IF : 88.5. Catégorie A +

Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, **Fizazi K**. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 2025;406:447-460.

IF : 88.5. Catégorie A +

Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Fleming M, Haas T, Ghebremariam S, Kreisl TN, Rajagopalan S, Sartor O, Morris MJ; PSMAfore Investigators. Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. Ann Oncol 2025; 36: 1319-1330.

IF : 65.4. Catégorie A

Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, Todenhöfer T, Gurney H, Kramer G, Bergman AM, Zalewski P, De Santis M, Armstrong AJ, Gerritsen W, Pachynski R, Byun SS, Retz M, Levesque E, McDermott R, Bracarda S, Manneh R, Levartovsky M, Li XT, Schloss C, Poehlein CH, **Fizazi K**. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. J Clin Oncol 2025; 43: 1638-1649.

IF : 43.4. Catégorie A

Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O. Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial. Lancet Oncol 2025; 26: 948-959.

IF : 35.9. Catégorie A

Fay AP, **Fizazi K**, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cisló P, Chang J, Healy CG, Niyazov A, Agarwal N. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol 2025; 26: 481-490.

IF : 35.9. Catégorie A

Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, **Fizazi K**. First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. *Lancet Oncol* 2025; 26: 470-480.

IF : 35.9. Catégorie A

Tisseverasinghe S, Tolba M, Saad F, **Fizazi K**, Bahoric B, Niazi T. Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease? *Eur Urol* 2025; 87: 364-367.

IF : 25.2. Catégorie A

Gillessen S, Turco F, Davis ID, Efsthathiou JA, **Fizazi K**, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrone K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efsthathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). *Eur Urol* 2025; 87: 157-216.

IF : 25.2. Catégorie A

Ravi P, Xie W, Buyse M, Halabi S, Kantoff PW, Sartor O, Attard G, Clarke N, D'Amico A, Dignam J, James N, **Fizazi K**, Gillessen S, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. *Eur Urol* 2025; 87: 217-224.

IF : 25.2. Catégorie A

Grimm MO, Smith M, Hussain M, Saad F, **Fizazi K**, Littleton N, Paracha N, Srinivasan S, Verholen F, Tombal B. Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial. *Eur Urol* 2025; 88: 400-407.

IF : 25.2. Catégorie A

Azad AA, Kostos L, Agarwal N, Attard G, Davis ID, Dorff T, Gillessen S, Parker C, Smith MR, Sweeney CJ, Tombal B, **Fizazi K**. Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer. *Eur Urol* 2025; 87: 455-467.

IF : 25.2. Catégorie A

Roy S, Sun Y, Hussain M, Chi KN, **Fizazi K**, Davis ID, Halabi S, Agarwal N, Chowdhury S, Tombal B, Morgan SC, Malone S, Barata PC, Ong M, Wallis CJD, Berlin A, Swami U, Kishan AU, Jia AY, Zaorsky NG, Garcia JA, Mendiratta P, Brown JR, Subhash VV, Stockler MR, Thomas H, McKay RR, Small EJ, Shore ND, Saad F, Sweeney CJ, Spratt DE. Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer. *Nat Commun* 2025; 17: 667.

IF : 15.7. Catégorie A

Blanc J, **Carnot A**, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaunderde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N. Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial. *J Immunother Cancer* 2025; 13: e012045.

IF : 10.6. Catégorie A

Séguier D, Parent P, Duterque-Coquillaud M, Labreuche J, Fromont-Hankard G, Dariane C, **Penel N**, Villers A, Turpin A, Olivier J. Emergence of Neuroendocrine Tumors in Patients Treated with Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol* 2025; 8: 581-590.

IF : 9.3. Catégorie A

Carles J, Tombal B, Hussain M, Saad F, **Fizazi K**, Montesa Pino Á, Méndez-Vidal MJ, Rodríguez-Vida A, Castellano D, Borrega P, Adorjan P, Moretones C, Dissanayake M, Smith MR. Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial. *Eur Urol Oncol* 2025; S2588-9311(25)00255-X.

IF : 9.3. Catégorie A

Ravi P, Kwak L, Xie W, D'Amico A, Dignam J, **Fizazi K**, James N, Teuff GL, Nguyen PL, Sandler H, Sartor O, Sydes MR, Sweeney CJ.

Docetaxel with Androgen Deprivation and Radiotherapy in High-risk Localized Prostate Cancer: An ICECaP Individual Patient Data Meta-analysis. *Eur Urol Oncol* 2025; S2588-9311(25)00303-7.

IF : 9.3. Catégorie A

Fizazi K, de Bono JS, Laird AD, Barthélémy P, Delva R, Dorff T, Maruzzo M, Stirling A, Machiels JP, Dumez H, Renard V, Hopkins JF, Albacker LA, Chen HC, Healy CG, DeAnnuntis L, Chelliserry J, van Oort IM, Scagliotti GV, Mehra N. Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy. *Eur Urol Oncol* 2025; 8: 1617-1628.

IF : 9.3. Catégorie A

Patrikidou A, Oing C, Markellos C, Heidenreich A, Leao R, Nicolai N, Boormans J, Fischer S, Fankhauser C, Cazzaniga W, Giannatempo P, Berney D, Gremmels H, Cornes R, Janisch F, Nardo DD, Papachristofilou A, **Fizazi K**, Tandstad T, Nicol D, Huddart R; European Association of Urology Testicular Cancer Guidelines Panel. Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey. *Eur Urol Oncol* 2025; 8: 1248-1252.

IF : 9.3. Catégorie A

van Wilpe S, Taha T, Rothmann EC, Altshuler E, Park J, Ledet EM, Rothermundt C, Bergman AM, Willemsen AECAB, Tsantoulis P, Oldenburg J, Bernard-Tessier A, **Fizazi K**, Robbrecht DGJ, Bruijnen CP, van der Hulle T, Antonarakis ES, Omlin A, Grönberg H, Armstrong AJ, Sartor O, Sena LA, Beltran H, de Bono JS, Mehra N. Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer. *Eur Urol Oncol* 2025; 8: 1020-1029.

IF : 9.3. Catégorie A

Rajpar S, Ibrahim T, Carmel A, Merabet Z, Vielh P, Foulon S, Lesaunier F, Delva R, Rolland F, Priou F, Ferrero JM, Houédé N, Mourey L, Théodore C, Krakowski I, Faivre L, Habibian M, Culine S, Gravis G, Chauchereau A, **Fizazi K**. The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials. *Eur Urol Oncol* 2025; 8 :296-305.

IF : 9.3. Catégorie A

Yazgan SC, Yekedüz E, Akkuş E, Sun M, Gillessen S, **Fizazi K**, McKay RR, Ay C, Castro E, Agarwal N, Choueiri TK, Ürün Y. Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis. *ESMO Open* 2025; 10: 105811.

IF : 8.3. Catégorie B

Rousseau A, Karimi M, Michiels S, Roubaud G, Maldonado X, Supiot S, McDermott R, Flechon A, Tombal B, Ronchin P, Berthold D, Berdah JF, Kacso G, Gravis G, Calabro F, Tartas S, Muracciole X, Ribault H, **Fizazi K**, Foulon S. Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial. *Eur J Cancer* 2025; 230: 116024.

IF : 7.1. Catégorie B

Roubaud G, Kostine M, McDermott RS, Bernard-Tessier A, Maldonado X, Silva M, Fléchon A, Berthold DR, Ronchin P, Tombal BF, Mourey L, Gravis G, Escande A, Abadie-Lacourtoisie S, Maurina T, Climent MA, Ribault H, Bossi A, Foulon S, **Fizazi K**. Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. *Eur J Cancer* 2025; 218: 115293.

IF : 7.1. Catégorie B

Boué A, Baciarello G, Meyer E, Christy F, Allouache N, Ratta R, Beuzeboc P, Brachet PE, Guerdoux E, Darlix A, Boone M, Gouérant S, Leconte A, Lequesne J, Clarisse B, **Fizazi K**, Lange M, Joly F. Impact of androgen receptor pathway inhibitors on cognitive function in older adults treated for metastatic prostate cancer. *Commun Med (Lond)* 2025; 6: 46.

IF : 6.3. Catégorie B

Longoria O, Rekowski J, Gupta S, Beije N, Pantel K, Efstathiou E, Sternberg C, Castellano D, **Fizazi K**, Tombal B, Sharp A, Sartor O, Macé S, Geffriaud-Ricouard C, Wenstrup R, de Wit R, de Bono J. Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. *JCI Insight* 2025; 10: e196505.

IF : 6.1. Catégorie B

Aldea M, Orillard E, Bernard-Tessier A, Cerbone L, Llacer C, Koster KL, Roubaud G, De Giorgi U, Joly F, Cherifi F, Rochand A, Omlin A, Beltran H, Morales-Barrera R, Annonay M, Bianchini D, de Bono J, Castro E, Baciarello G, Gillessen S, Thiery-Vuillemin A, **Fizazi K**. Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations. *JCO Precis Oncol* 2025; 9: e2500310.

IF : 5.8. Catégorie B

Alyamani N, Clementel E, Sargos P, Blanchard P, Supiot S, Ronchin P, Pommier P, Duberge T, Silva M, Hammoud Y, Hasbini A, Khalifa J, Gnep K, Scrase C, Saez J, Vieilleigne L, Christiaens M, Zilli T, Ribault H, Bossi A, **Fizazi K**, Andratschke N. Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis. *Radiother Oncol* 2025; 206: 110780.

IF : 5.3. Catégorie B

Bernard-Tessier A, Naoun N, Barraud S, Flippot R, Pobel C, Rey M, Baldini C, Massard C, Patrikidou A, Fuerea A, Di Palma M, Albigès L, Lorient Y, **Fizazi K**. The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond. *Ther Adv Med Oncol* 2025; 17: 17588359251379416.

IF : 4.2. Catégorie C

Morgans AK, Chehraz-Raffle A, Niazi T, Shore ND, Ross AE, Røder A, Gomes AJ, Supiot S, Barthélémy P, Hatano K, Ruiz CBC, Yoshida S, Herrera-Imbroda B, Gratton M, Gschwend JE, Hope TA, Joensuu H, Kuss I, Le Berre MA, Dimova-Dobrev M, **Fizazi K**. Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP). *Future Oncol* 2025; 21: 3491-3498.

IF : 2.6. Catégorie D

Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study. *Future Oncol* 2025; 21: 637-652.

IF : 2.6. Catégorie D

Saad F, Hussain MHA, Tombal B, **Fizazi K**, Mastris K, Flannery T, Smith MR. Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary. *Future Oncol* 2025; 21: 1157-1170.

IF : 2.6. Catégorie D

Pajot T, Olivier J, Séguier D, Villers A, **Penel N**. Prescribing androgen deprivation therapy for prostate cancer: Results of a French questionnaire survey. *Fr J Urol* 2025; 35: 102930.

IF : 1.1. Catégorie D

Roubaud G, Fizazi K. Vivre avec... un cancer du testicule [Living with... testicular cancer]. *Rev Prat* 2025; 75: 993-994.

Morgans AK, Roy S, Jia AY, Barata P, Zaorsky NG, Garcia JA, Brown JR, Rao S, Mendiratta P, Armstrong AJ, Hussain MH, Attard G, James ND, Fizazi K, Sun Y, Spratt DE. Age and Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer. *NEJM Evid* 2025; 4: EVIDoa2500109.

VADS

Galot R, Le Tourneau C, Licitra L, Guigay J, Kong A, Tinhofer I, Even C, Daste A, Henry S, Borel C, **Abdeddaim C**, Seront E, Prevost JB, Rutten A, Saada-Bouazid E, Rolland F, Bonomo P, Rasschaert M, Dirix L, Olungu C, Tsechilidou K, Govaerts AS, Fortpied C, Joaquim A, Machiels JP. A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). *ESMO Open* 2025; 10: 104554.

IF : 8.3. Catégorie B

Libert L, **Abdeddaim C**, Saleh K, Even C, Duplomb S, Dubreuil J, Rambeau A, Guiard E, Pointreau Y, Olympios-Gerotzortzos N, Moldovan C, Lévêque E, Clatot F. Retrospective multicentric survival analysis of patients receiving TPEX regimen as first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma. *ESMO Open* 2025; 10: 104544.

IF : 8.3. Catégorie B

Simon A, **Abdeddaim C**, Nguyen D, Gallet P, Peiffert D, Lambert A, Geoffrois L. First-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Multicenter Real-World Study. *Head Neck* 2025; 47: 2939-2949.

IF : 2.2. Catégorie B

Dreszer A, Olejnik C, Aymes E, **Barthoulot M**, Liem X, **Cordoba A**. Brachytherapy efficacy and safety in the treatment of primitive tongue carcinomas: experience from the Oscar Lambret Center. *J Stomatol Oral Maxillofac Surg* 2025; 126: 102416.

IF : 2. Catégorie C

Divers

Belmontes B, Slemmons KK, Su C, Liu S, Policheni AN, Moriguchi J, Tan H, Xie F, Aiello DA, Yang Y, Lazaro R, Aeffner F, Rees MG, Ronan MM, Roth JA, Vestergaard M, Cowland S, Andersson J, Sarvary I, Chen Q, Sharma P, Lopez P, Tamayo N, Pettus LH, Ghimire-Rijal S, Mukund S, Allen JR, DeVoss J, Coxon A, Rodon J, Ghiringhelli F, **Penel N**, Prenen H, Glad S, Chuang CH, Keyvanjah K, Townsley DM, Butler JR, Bourbeau MP, Caenepeel S, Hughes PE. AMG 193 a Clinical Stage MTA-Cooperative PRMT5 Inhibitor Drives Antitumor Activity

Preclinically and in Patients with MTAP-Deleted Cancers. *Cancer Discov* 2025; 15: 139-161.

IF : 33.3. Catégorie A

Borcoman E, Cabarrou B, Francisco M, Bigot F, Ghiringhelli F, Vansteene D, Legrand F, Halladjian M, Dupain C, Le Saux O, Coutzac C, Borel C, Chaltiel R, You B, Gomez-Roca C, Cousin S, Coquan E, Lambert A, Saada-Bouid E, Durando X, **Saint-Ghislain M**, Frige G, Guerini-Rocco E, Tonini MM, Bièche I, Castel-Ajgal Z, Marret G, Sablin MP, Jeannot E, Andre F, Filleron T, Jimenez M, Mazzarella L, Servant N, Kamal M, Le Tourneau C. Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial. *Nat Cancer* 2025; 6: 1370-1383.

IF : 28.5. Catégorie A

Pichon S, Zebian G, Bureau C, Levy C, Lacombe C, Desmedt E, Wils P, Merlen E, Lionet A, Terriou L, Collet A, Ledoult E, Zephir H, Ningharhari M, Sobanski V, Scherpereel A, **Forestier A**, Launay D, Jourdain M. Life-threatening immune-related adverse events in the intensive care unit: a narrative review. *Intensive Care Med* 2025; 51: 2289-2304.

IF : 22.1. Catégorie A

Terrassoux L, Hazard C, Laratte A, Balsamelli J, Arcicasa M, Fong E, Baland L, Soncin F, Cappello G, Maurage CA, Janel S, Bazir A, Cleri F, Treizebre A, **Lartigau E**, Rekik Y, **Meignan S**, Furlan A. Novel Diffuse Midline Glioma-on-Chip Recapitulating Tumor Biophysical Microenvironment to Assess the Heterogeneity of Response to Therapies. *Small* 2025; 21: e05343.

IF : 12.1. Catégorie A

Sandoval Pacheco C, Leroy AM, Derhourhi M, Cardon T, Leroy C, Jouy N, Com E, Guevel B, Bourette R, Carrard J, Barros D, Duchêne B, Toussaint B, Froguel P, Jonckheere N, Chassat T, Van Seuning I, Lavigne R, Pineau C, Pierre P, **Soncin F**, Salzet M, Bonnefond A, Lejeune F. Exploring the role of readthrough-inducing molecule 2,6-diaminopurine to increase immune response against cancer cells. *Mol Ther* 2025; 33: 6212-6225.

IF : 12. Catégorie A

Lansche C, Ladaigue S, Gropplero G, Zimmermann N, Nurmik M, Veith I, Nguyen ML, Brosseau S, Poté N, Mordant P, Roussel A, Mami-Chouaib F, Mechta-Grigoriou F, Zalcman G, **Soncin F**, Descroix S, Parrini MC. Bioengineering a Patient-Derived Vascularized Lung Tumor-on-Chip Model to Decipher Immunomodulation by the Endothelium. *Adv Healthc Mater* 2025; 14: e2403446.

IF : 9.6. Catégorie A

Giroud J, Delvaux P, Carlier L, De Schutter C, Martin N, Rouget R, Bolouki A, De Glas V, Bouriez I, Bourdoux F, Burteau S, Théry J, Decanter G, **Penel N**, de Launoit Y, Ledoux B, Abbadie C, Poumay Y, Pluquet O, Debacq-Chainiaux F. Targeting ATF6? Attenuates UVB-Induced Senescence and Improves Skin Homeostasis by Regulating IL8 Expression. *Aging Cell* 2025; 24: e70024.

IF : 7.1. Catégorie A

Kolly J, Leloirain S, **Penel N**, Dietrich PY, Laroussi-Libeault L, Lamore K. Cancer progression and shared decision-making: Crossed. *Patient Educ Couns* 2025; 145: 109464.

IF : 3.1. Catégorie A

Penel N, **Cren PY**, Ducrocq C, Laurent EMN, Choukroun G, Hazzan M, Crie D. Motivational factors influencing the choice of oncology as a specialty among French medical students. *BMC Med Educ* 2025; 25: 447.

IF : 3.2. Catégorie B

Cren PY, **Rosier G**, **Penel N**, **Pannier D**, **Dereumaux N**, **Aelbrecht-Meurisse C**, **Strobbe G**, Pelletier de Chambure D. Development and evaluation of a new protocol for the management of immediate hypersensitivity reactions in an oncology outpatient department. *Bull Cancer* 2025; 112: 1371-1375.

IF : 0.8. Catégorie E